Prostatype Genomics (PROGEN.ST) Stock Analysis & AI Equity Report
Prostatype Genomics (PROGEN.ST) overview
Prostatype Genomics (PROGEN.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Prostatype Genomics reported revenue of SEK 0.6m and operating profit of SEK -39.1m; the year-end share price was 0.30 SEK and market capitalisation was SEK 10.1m. Prostatype Genomics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Prostatype Genomics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About Prostatype Genomics
Prostatype Genomics AB develops, manufactures and markets Prostatype®, a CE-marked genomic test for prostate cancer. The test analyzes biopsy tissue together with clinical parameters to help assess tumor aggressiveness and support treatment decisions. The company’s value drivers are test sales, laboratory services and ongoing commercialization efforts in Europe and the United States, including reimbursement approvals.
Generate the Prostatype Genomics report
Prostatype Genomics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Prostatype Genomics and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.